Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Colorectal Cancer Reports
Published in: Current Colorectal Cancer Reports 4/2013

01-12-2013 | Translational Colorectal Oncology (Y Jiang, Section Editor)

The Clinical Potential of Circulating Tumor Cells and Circulating Tumor-Associated Cellular Elements in Colorectal Cancer

Authors: Judy S. Wang, Michael B. Foote, Khalid A. Jazieh, Luis A. Diaz Jr

Published in: Current Colorectal Cancer Reports | Issue 4/2013

Login to get access

Abstract

Colorectal cancer (CRC) remains one of the commonest types of cancer in the USA. Effective treatment and potential curative resection is dependent on early detection, prior to the development of distant metastases. Radiologic and endoscopic evaluations are operator-dependent and limited by macroscopic detection when the relative cellular tumor burden is already high. Also, use of serum biomarkers such as carcinoembryonic antigen may not correlate with the extent of disease involvement. Circulating tumor cells (CTCs) continue be a prominent area of investigation, despite having been described first by Ashworth in 1869. As methods for detection expand and improve, CRC is increasingly characterized by the properties of CTCs and tumor-associated cellular elements (TACEs), such as circulating tumor DNA, cell-free DNA, and microRNA. This review serves to highlight the clinical implications of CRC CTCs and TACEs for prognostication, monitoring for disease recurrence, and response to therapy.
Literature
1.
2.
Allen JE, El-Deiry WS. Circulating tumor cells and colorectal cancer. Curr Colorectal Cancer Rep. 2010;6(4):212–20.PubMedCrossRef
3.
Steinert G, Scholch S, Koch M, et al. Biology and significance of circulating and disseminated tumour cells in colorectal cancer. Langenbecks Arch Surg. 2012;397:535–42.PubMedCrossRef
4.
Gorges T, Pantel K. Circulating tumor cells as therapy-related biomarkers in cancer patients. Cancer Immunol Immunother. 2013;62(5):931–9.PubMedCrossRef
5.
Alix-Panabières C, Schwarzenbach H, Pantel K. Circulating tumor cells and circulating tumor DNA. Annu Rev Med. 2012;63:199–215.PubMedCrossRef
6.
Aggarwal C, Meropol NJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, et al. Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer. Ann Oncol. 2013;24(2):420–8.PubMedCrossRef
7.
8.
Bidard F, Ferrand F, Huguet F. Disseminated and circulating tumor cells in gastrointestinal oncology. Crit Rev Oncol Hematol. 2012;82:103–15.PubMedCrossRef
9.
• Denève E, Riethdorf S, Ramos J, et al. Capture of viable circulating tumor cells in the liver of colorectal cancer patients. Clin Chem. 2013;59:1384–92. This small study demonstrates potential liver sequestration of CTCs, thereby altering measurement of CTCs.PubMedCrossRef
10.
Otsuka K, Imai H, Soeda H, et al. Practical utility of circulating tumour cells as biomarkers in cancer chemotherapy for advanced colorectal cancer. Anticancer Res. 2013;33:625–30.PubMed
11.
Mostert B, Jiang Y, Sieuwerts A, et al. KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue. Int J Cancer. 2013;133:130–41.PubMedCrossRef
12.
Liu Z, Li L, Liu X, Zhang DX. Comparative analysis of tumor markers and evaluation of their predictive value in patients with colorectal cancer. Onkologie. 2012;35:108–13.PubMedCrossRef
13.
Liu Y, Qian J, Feng J, et al. Detection of circulating tumor cells in peripheral blood of colorectal cancer patients without distant organ metastases. Cell Oncol. 2013;36:43–53.CrossRef
14.
Gazzaniga P, Gianni W, Raimondi C, et al. Circulating tumor cells in high-risk nonmetastatic colorectal cancer. Tumour Biol. 2013;34(5):2507–9.PubMedCrossRef
15.
Yokobori T, Linuma H, Shimamura T, et al. Plastin3 is a novel marker for circulating tumor cells undergoing the epithelial-mesenchymal transition and is associated with colorectal cancer prognosis. Cancer Res. 2013;73:2059–69.PubMedCrossRef
16.
Koerkamp B, Rahbari N, Bu M, et al. Circulating tumor cells and prognosis of patients with resectable colorectal liver metastases or widespread metastatic colorectal cancer: a meta-analysis. Ann Surg Oncol. 2013;20:2156–65.CrossRef
17.
Barbaza J, Vieito M, Abalo A, et al. A logistic model for the detection of circulating tumour cells in human metastatic colorectal cancer. J Cell Mol Med. 2012;16(10):2342–9.CrossRef
18.
Sastre J, Maestro L, Gomez-Espana A. Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study. Oncologist. 2012;17:947–55.PubMedCrossRef
19.
Hinz S, Bockgorst J, Roder C, et al. Disseminated tumor cells in the bone marrow negatively influences survival after resection of colorectal liver metastases. Ann Surg Oncol. 2012;19:2539–46.PubMedCrossRef
20.
Shimada R, Iinuma H, Akahane T, et al. Prognostic significance of CTCs and CSCs of tumor drainage in Dukes’ stage B and C colorectal cancer patients. Oncol Rep. 2012;27:947–53.PubMed
21.
Pilati P, Mocellin S, Bertazza L, et al. Prognostic value of putative circulating cancer stem cells in patients undergoing hepatic resection for colorectal liver metastasis. Ann Surg Oncol. 2012;19:402–8.PubMedCrossRef
22.
Huang M, Wang H, Tok T, et al. EVI2B, ATP2A2, S100B, TM4SF3, and OLFM4 as potential prognostic markers for postoperative Taiwanese colorectal cancer patients. DNA Cell Biol. 2012;31(4):625–35.PubMedCrossRef
23.
• Gazzaniga P, Raimondi C, Gradilone A, et al. Circulating tumor cells in metastatic colorectal cancer: do we need an alternative cutoff. J Cancer Res Clin Oncol. 2013;139(8):1411–6. This small study demonstrated a potential threshold for CTC detection to prognosticate CRC clinical outcomes.PubMedCrossRef
24.
Kawahara H, Watanabe K, Toyama Y. Determination of circulating tumor cells for prediction of recurrent colorectal cancer progression. Hepatogastroenterology. 2012;59:2115–8.PubMedCrossRef
25.
Albuquerque A, Kubisch I, Stolzel U, et al. Prognostic and predictive value of circulating tumor cell analysis in colorectal cancer patients. J Transl Med. 2012;10:222.PubMedCrossRef
26.
Pesta M, Fichtl J, Kulda V, et al. Monitoring of circulating tumor cells in patients undergoing surgery for hepatic metastases from colorectal cancer. Anticancer Res. 2013;33(5):2239–43.PubMed
27.
Park S, Choi G, Park J. Influence of surgical manipulation and surgical modality on the molecular detection of circulating tumor cells from colorectal cancer. J Korean Surg Soc. 2012;82:356–64.PubMedCrossRef
28.
29.
Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol. 2013;10(8):472–84.PubMedCrossRef
30.
Leary RJ, Kinde I, Diehl F, et al. Development of personalized tumor biomarkers using massively parallel sequencing. Sci Transl Med. 2010;2(20):20ra14.PubMedCrossRef
31.
Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14(9):985–90.PubMedCrossRef
32.
• Philipp AB, Stieber P, Nagel D, Neumann J, Spelsberg F, Jung A, et al. Prognostic role of methylated free circulating DNA in colorectal cancer. Int J Cancer. 2012;131(10):2308–19. This study demonstrated strong associations with epigenetic modification of ctDNA and poorer prognostic factors.PubMedCrossRef
33.
Holdhoff M, Schmidt K, Donehower R, Diaz Jr LA. Analysis of circulating tumor DNA to confirm somatic KRAS mutations. J Natl Cancer Inst. 2009;101(18):1284–5.PubMedCrossRef
34.
Diaz Jr LA, Williams RT, Wu J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012;486(7404):537–40.PubMed
35.
Bardelli A, Corso S, Bertotti A, et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov. 2013;3(6):658–73.PubMedCrossRef
36.
Leary RJ, Sausen M, Kinde I, et al. Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med. 2012;4(162):162ra154.PubMedCrossRef
37.
Mouliere F, El Messaoudi S, Gongora C, et al. Circulating cell-free DNA from colorectal cancer patients may reveal high KRAS or BRAF mutation load. Transl Oncol. 2013;6(3):319–28.PubMed
38.
Diehl F, Li M, Dressman D, et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A. 2005;102(45):16368–73.PubMedCrossRef
39.
Frattini M, Gallino G, Signoroni S, Balestra D, Battaglia L, Sozzi G, et al. Quantitative analysis of plasma DNA in colorectal cancer patients: a novel prognostic tool. Ann N Y Acad Sci. 2006;1075:185–90.PubMedCrossRef
40.
da Silva Filho BF, Gurgel AP, Neto MA, de Azevedo DA, de Freitas AC, Silva Neto JD, et al. Circulating cell-free DNA in serum as a biomarker of colorectal cancer. J Clin Pathol. 2013;66(9):775–8.PubMedCrossRef
41.
Mead R, Duku M, Bhandari P, Cree IA. Circulating tumour markers can define patients with normal colons, benign polyps, and cancers. Br J Cancer. 2011;105(2):239–45.PubMedCrossRef
42.
43.
Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2002;99(24):15524–9.PubMedCrossRef
44.
Schetter AJ, Okayama H, Harris CC. The role of microRNAs in colorectal cancer. Cancer J. 2012;18(3):244–52.PubMedCrossRef
45.
Ng EK, Chong WW, Jin H, Lam EK, Shin VY, Yu J, et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut. 2009;58(10):1375–81.PubMedCrossRef
46.
Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105(30):10513–8.PubMedCrossRef
47.
Michael MZ, O’ Connor SM, van Holst Pellekaan NG, Young GP, James RJ. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res. 2003;1(12):882–91.PubMed
48.
Akao Y, Nakagawa Y, Hirata I, Iio A, Itoh T, Kojima K, et al. Role of anti-oncomirs miR-143 and -145 in human colorectal tumors. Cancer Gene Ther. 2010;17(6):398–408.PubMedCrossRef
49.
•• Luo X, Burwinkel B, Tao S, Brenner H. MicroRNA signatures: novel biomarker for colorectal cancer? Cancer Epidemiol Biomarkers Prev. 2011;20(7):1272–86. This study comprehensively cataloged multiple miRNAs and their clinical significance in CRC prognostication.PubMedCrossRef
50.
Wang B, Zhang Q. The expression and clinical significance of circulating microRNA-21 in serum of five solid tumors. J Cancer Res Clin Oncol. 2012;138(10):1659–66.PubMedCrossRef
51.
Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA. 2008;299(4):425–36.PubMedCrossRef
52.
Shibuya H, Iinuma H, Shimada R, Horiuchi A, Watanabe T. Clinicopathological and prognostic value of microRNA-21 and microRNA-155 in colorectal cancer. Oncology. 2010;79(3–4):313–20.PubMedCrossRef
53.
Nielsen BS, Jorgensen S, Fog JU, Sokilde R, Christensen IJ, Hansen U, et al. High levels of microRNA-21 in the stroma of colorectal cancers predict short disease-free survival in stage II colon cancer patients. Clin Exp Metastasis. 2011;28(1):27–38.PubMedCrossRef
54.
Toiyama Y, Takahashi M, Hur K, Nagasaka T, Tanaka K, Inoue Y, et al. Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. J Natl Cancer Inst. 2013;105(12):849–59.PubMedCrossRef
55.
Wang LG, Gu J. Serum microRNA-29a is a promising novel marker for early detection of colorectal liver metastasis. Cancer Epidemiol. 2012;36(1):e61–7.PubMedCrossRef
56.
Cheng H, Zhang L, Cogdell DE, Zheng H, Schetter AJ, Nykter M, et al. Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS One. 2011;6(3):e17745.PubMedCrossRef
57.
Pu XX, Huang GL, Guo HQ, Guo CC, Li H, Ye S, et al. Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression. J Gastroenterol Hepatol. 2010;25(10):1674–80.PubMedCrossRef
58.
Schee K, Lorenz S, Worren MM, Gunther CC, Holden M, Hovig E, et al. Deep sequencing the microRNA transcriptome in colorectal cancer. PLoS One. 2013;8(6):e66165.PubMedCrossRef
59.
Mencia N, Selga E, Noe V, Ciudad CJ. Underexpression of miR-224 in methotrexate resistant human colon cancer cells. Biochem Pharmacol. 2011;82(11):1572–82.PubMedCrossRef
60.
Chai H, Liu M, Tian R, Li X, Tang H. miR-20a targets BNIP2 and contributes chemotherapeutic resistance in colorectal adenocarcinoma SW480 and SW620 cell lines. Acta Biochim Biophys Sin. 2011;43(3):217–25.PubMedCrossRef
Metadata
Title
The Clinical Potential of Circulating Tumor Cells and Circulating Tumor-Associated Cellular Elements in Colorectal Cancer
Authors
Judy S. Wang
Michael B. Foote
Khalid A. Jazieh
Luis A. Diaz Jr
Publication date
01-12-2013
Publisher
Springer US
Published in
Current Colorectal Cancer Reports / Issue 4/2013
Print ISSN: 1556-3790
Electronic ISSN: 1556-3804
DOI
https://doi.org/10.1007/s11888-013-0193-2

Other articles of this Issue 4/2013

Current Colorectal Cancer Reports 4/2013 Go to the issue

Molecular Biology (S Anant, Section Editor)

Role of Apoptosis in Colon Cancer Biology, Therapy, and Prevention

Immunotherapy of Malignancy (MA Morse, Section Editor)

The Association of Immune Cell Infiltration and Prognosis in Colorectal Cancer

Immunotherapy of Malignancy (MA Morse, Section Editor)

Viral Vector Vaccines To Treat Colorectal Cancer

Translational Colorectal Oncology (Y Jiang, Section Editor)

Do We Need another Antiangiogenesis Agent for Colorectal Cancer: are Bevacizumab and Aflibercept the Same?

Immunotherapy of Malignancy (MA Morse, Section Editor)

Status of Active Specific Immunotherapy for Stage II, Stage III, and Resected Stage IV Colon Cancer

Molecular Biology (S Anant, Section Editor)

Molecular Origins of Colon and Rectal Cancer: Not a Wnt–Wnt Situation
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits